Placebo News and Research

RSS

Valproic acid may help slow the progression of dementia

Researchers have found that a common anticonvulsant drug improved cognitive function and appeared to restore nerve cells in the brains of patients with HIV-related dementia. The results of the Phase I clinical trial are published in the March issue of the scientific journal Neurology.

14 Mar 2006

Clopidogrel reduces risk of adverse events for patients with acute coronary syndromes undergoing balloon angioplasty

Patients with acute coronary syndromes who were pre-treated with the anti-platelet agent clopidogrel before undergoing a procedure such as balloon angioplasty or stent placement had a reduced risk of adverse events if they received the anti-clotting drug abciximab

14 Mar 2006

Can fixing the heart fix the head?

A study presented during the American College of Cardiology's inaugural Innovation in Intervention: The i2 Summit 2006 in Atlanta, Ga., will answer intriguing questions about whether repairing a hole in the heart known as a patent foramen ovale (PFO) can ease the pain of severe migraine headaches.

14 Mar 2006

Aspirin still the best for reducing the heart attack risk

New research has revealed that the addition of the blood-thinning drug Plavix to a daily dose of aspirin does not lower the risk of death, heart attack or stroke in high-risk patients.

13 Mar 2006

B vitamins and folic acid don't cut the risk of further heart attacks

Scientists have found that levels of the amino acid homocysteine may be high in people destined for a heart attack or stroke, and some studies in the past have linked homocysteine to an increased risk of heart disease.

13 Mar 2006

Using a growth factor to stimulate production of circulating endothelial progenitor cells improves cell production and mobility in arterial disease

Using a growth factor to stimulate production of circulating endothelial progenitor cells increases the numbers of these vascular regenerative cells, improves mobility, and potentially could improve blood vessel function in patients with peripheral arterial disease (PAD).

13 Mar 2006

D-cycloserine helps patients learn how to conquer their fears

The fear of public speaking is the most common among individuals with SAD, as well as in the general population. The results of the study are published in the March issue of the Archives of General Psychiatry.

13 Mar 2006

Pills containing plant sterols lower LDL cholesterol

A pill containing plant substances called sterols can help lower cholesterol, according to researchers at Washington University School of Medicine in St. Louis.

9 Mar 2006

Yale School of Medicine expands research using transcranial magnetic stimulation for schizophrenia

Yale School of Medicine researchers are recruiting patients nationally for a clinical trial using transcranial magnetic stimulation (TMS) to help still the voices that are so troubling to some persons with schizophrenia.

9 Mar 2006

Alfuzosin may improve double-J stent related symptoms

The first indwelling endoluminal ureteral stent was described over 30 years ago and has since become a routine and indispensable urologic tool. However, the side effects and patient morbidity associated with ureteral stents are not insignificant.

9 Mar 2006

Repligen commences phase 2 trial of RG2417 for bipolar depression

Repligen Corporation today announced that the Company has initiated a Phase 2 clinical trial of RG2417, an oral formulation of uridine, in patients with bipolar depression.

9 Mar 2006

Is there any role for thalidomide as a monotherapy in the management of metastatic renal cell carcinoma?

Thalidomide remains an enigma in the treatment of metastatic renal cell carcinoma (RCC). Initial clinical trials suggested a benefit, but more recently, subsequent randomized trials studying thalidomide in combination with other agents such as interferon have demonstrated no added benefit.

8 Mar 2006

Discovery of compound that reduces hallmark lesions of Alzheimer's disease in mice

Researchers at UC Irvine have found that a new compound not only relieves the cognitive symptoms of Alzheimer's disease, but also reduces the two types of brain lesions that are hallmarks of this devastating disease, thereby blocking its progression.

7 Mar 2006

SSRI use associated with increased risk for heart patients

In a surprising finding, patients with coronary artery disease who take commonly used antidepressant drugs may be at significantly higher risk of death, Duke University Medical Center researchers have found.

7 Mar 2006

FDA grants priority review for Revlimid

Celgene Corporation announced that the U.S. Food and Drug Administration (FDA) has granted a Priority Review designation to its Supplemental New Drug Application (sNDA) for REVLIMID (lenalidomide) for the treatment of relapsed or refractory multiple myeloma.

6 Mar 2006

Trials on MS drug Tysabri renews hope for sufferers

According to the results of two new trials the multiple sclerosis (MS) drug Tysabri significantly reduces the progression of the disease.

5 Mar 2006

Bone marrow stem cells do not improve cardiac function in heart attack patients

There has been increasing evidence that stem cells contribute to regeneration of cardiac tissue and the development of new blood vessels following a heart attack, thus opening up new prospects for stem-cell based therapies.

1 Mar 2006

Reaction to DTaP vaccine finds no help from ibuprofen, acetaminophen

A red splotch forms where most preschoolers get their fifth, and last, shot of the acellular diphtheria-tetanus-pertussis (DTaP) vaccine, and it can last a few days.

1 Mar 2006

FDA approves Rituxan (Rituximab)

Rituxan is the first treatment for RA that selectively targets immune cells known as CD20-positive B-cells. Through this unique mechanism of action, Rituxan may affect multiple pathways by which B-cells are believed to contribute to the initiation and development of RA.

1 Mar 2006

$Hormone therapy for advanced prostate cancer can lead to bone loss and fractures$

Hormone therapy for advanced prostate cancer can lead to bone loss and fractures

A common type of treatment used to protect bone density in menopausal women is also an effective therapy for advanced prostate cancer patients during the first year of hormone therapy, according to a new Oregon Health & Science University Cancer Institute study.

1 Mar 2006